BMS-570520

Overview

BMS-570520 is an orally bioavailable CCR3 antagonist with an IC 50 of 1.9 nM against hCCR3 and an IC 50 of 1300 nM against hCYP2D6 . BMS-570520 inhibits CYP2D6 , but shows low activity against off-target G protein-coupled receptors, biogenic amine transporters, and the hERG potassium channel . BMS-570520 regulates chemotaxis, calcium mobilization, and anti-inflammatory pathways. BMS-570520 can be used in research related to asthma, allergic rhinitis, and contact dermatitis.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Allergy | Products > Disease Areas > Skin Inflammation | Products > Disease Areas > Allergic Asthma | Products > Disease Areas > Allergic Rhinitis | Products > Disease Areas > Atopic Dermatitis | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Serotonin Transporter | Products > Signaling Pathways > CCR | Products > Signaling Pathways > Cytochrome P450 | Products > Signaling Pathways > 5-HT Receptor | Products > Signaling Pathways > Dopamine Receptor

Product Information

• Catalog No.: HY-182735
• CAS No.: 388101-58-4
• Molecular Formula: C27H36FN5O3S
• Molecular Weight: 529.67
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source